Financial Analysts Roundtable: Medicare Part D, Big Pharma Diversification And The Outlook For M&A
Executive Summary
Three large cap pharmaceutical analysts sat down with "The Pink Sheet" in January to discuss the outlook for the drug industry in 2007. Below are excerpts from a conversation with Prudential's Tim Anderson, Goldman Sachs' Jim Kelly and Morgan Stanley's Jami Rubin. 1Kelly and 2Rubin provided "The Pink Sheet" with extensive disclosure statements, which can be accessed by visiting 3www.ThePinkSheet.com. In the second part of the series, slated to appear in the Feb. 12 issue, the analysts discuss the impact of the changes on Capitol Hill and the regulatory climate.
You may also be interested in...
Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks
As the pharmaceutical industry wades through its second spate of major restructuring initiatives in the last three years, investors may be weighing whether the programs reflect efforts to improve efficiency in the face of short-term setbacks, or suggest a more fundamental long-term downsizing of the brand industry
Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks
As the pharmaceutical industry wades through its second spate of major restructuring initiatives in the last three years, investors may be weighing whether the programs reflect efforts to improve efficiency in the face of short-term setbacks, or suggest a more fundamental long-term downsizing of the brand industry
Schering Jumps On Organon Buy; Will Late-Stage M&A Keep Fueling Pharma?
Pharmaceutical companies unveiling mergers and acquisitions in the first quarter were among those rewarded by Wall Street